Lilly bags another in vivo CAR-T biotech via $7B Kelonia deal

Eli Lilly has acquired Kelonia Therapeutics in a deal worth up to $7 billion, adding another in vivo CAR-T company to its portfolio. The acquisition expands Lilly's capabilities in developing cell therapies that can be administered directly in patients rather than requiring ex vivo manufacturing.